{"id":"https://openalex.org/W7096040967","doi":null,"title":"Blockade of Receptor for Advanced Glycation End Products in a Model of Type 1 Diabetic","display_name":"Blockade of Receptor for Advanced Glycation End Products in a Model of Type 1 Diabetic","publication_year":2016,"publication_date":"2016-09-09","ids":{"openalex":"https://openalex.org/W7096040967"},"language":"en","primary_location":{"id":"pmh:oai:CiteSeerX.psu:10.1.1.860.2203","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.860.2203","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://diabetes.diabetesjournals.org/content/early/2012/08/30/db12-0317.full.pdf","raw_type":"text"},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Cory C. Toth","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Cory C. Toth","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.45708837,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":true,"primary_topic":{"id":"https://openalex.org/T11142","display_name":"Advanced Glycation End Products research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1308","display_name":"Clinical Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11142","display_name":"Advanced Glycation End Products research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1308","display_name":"Clinical Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T14144","display_name":"Neurological Disease Mechanisms and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12533","display_name":"Aldose Reductase and Taurine","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/advanced-glycation-end-products","display_name":"advanced glycation end products","score":0.9599999785423279},{"id":"https://openalex.org/keywords/rage-receptor","display_name":"RAGE receptor","score":0.6990000009536743},{"id":"https://openalex.org/keywords/type-1-diabetes","display_name":"type 1 diabetes","score":0.8970000147819519},{"id":"https://openalex.org/keywords/soluble-rage","display_name":"soluble RAGE","score":0.6710000038146973},{"id":"https://openalex.org/keywords/cognitive-decline","display_name":"cognitive decline","score":0.6370000243186951},{"id":"https://openalex.org/keywords/brain-atrophy","display_name":"brain atrophy","score":0.8230000138282776},{"id":"https://openalex.org/keywords/oligodendrocyte-loss","display_name":"oligodendrocyte loss","score":0.8949999809265137},{"id":"https://openalex.org/keywords/hyperglycemia","display_name":"hyperglycemia","score":0.8289999961853027},{"id":"https://openalex.org/keywords/nf-kappab-signaling","display_name":"NF-\u03baB signaling","score":0.7910000085830688},{"id":"https://openalex.org/keywords/streptozotocin-induced-diabetes","display_name":"streptozotocin-induced diabetes","score":0.9070000052452087},{"id":"https://openalex.org/keywords/white-matter-abnormalities","display_name":"white matter abnormalities","score":0.6779999732971191},{"id":"https://openalex.org/keywords/myelin","display_name":"myelin","score":0.4429999887943268}],"concepts":[{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.7954000234603882},{"id":"https://openalex.org/C147990577","wikidata":"https://www.wikidata.org/wiki/Q25790","display_name":"Glycation","level":3,"score":0.689300000667572},{"id":"https://openalex.org/C2778857457","wikidata":"https://www.wikidata.org/wiki/Q153641","display_name":"Rage (emotion)","level":2,"score":0.6444000005722046},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6182000041007996},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5358999967575073},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.507099986076355},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5020999908447266},{"id":"https://openalex.org/C103133801","wikidata":"https://www.wikidata.org/wiki/Q408572","display_name":"Sigma-1 receptor","level":4,"score":0.48559999465942383},{"id":"https://openalex.org/C2781172350","wikidata":"https://www.wikidata.org/wiki/Q194520","display_name":"Atrophy","level":2,"score":0.4580000042915344},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.4165000021457672},{"id":"https://openalex.org/C2984863031","wikidata":"https://www.wikidata.org/wiki/Q83030","display_name":"Cognitive decline","level":4,"score":0.41589999198913574},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4058000147342682},{"id":"https://openalex.org/C2910068830","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 Diabetes Mellitus","level":3,"score":0.36309999227523804},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.36079999804496765},{"id":"https://openalex.org/C2776997535","wikidata":"https://www.wikidata.org/wiki/Q2556837","display_name":"Advanced glycation end-product","level":4,"score":0.34929999709129333},{"id":"https://openalex.org/C2781232474","wikidata":"https://www.wikidata.org/wiki/Q124407","display_name":"Type 1 diabetes","level":3,"score":0.3319999873638153},{"id":"https://openalex.org/C2778609137","wikidata":"https://www.wikidata.org/wiki/Q105790271","display_name":"Myelin","level":3,"score":0.3269999921321869},{"id":"https://openalex.org/C25498285","wikidata":"https://www.wikidata.org/wiki/Q1981368","display_name":"Neuroprotection","level":2,"score":0.3253999948501587},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.32440000772476196},{"id":"https://openalex.org/C2778583010","wikidata":"https://www.wikidata.org/wiki/Q3237081","display_name":"Leukoencephalopathy","level":3,"score":0.31859999895095825},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.2935999929904938},{"id":"https://openalex.org/C2781192897","wikidata":"https://www.wikidata.org/wiki/Q822050","display_name":"White matter","level":3,"score":0.28459998965263367},{"id":"https://openalex.org/C143409427","wikidata":"https://www.wikidata.org/wiki/Q161238","display_name":"Magnetic resonance imaging","level":2,"score":0.28220000863075256},{"id":"https://openalex.org/C2778122271","wikidata":"https://www.wikidata.org/wiki/Q410943","display_name":"Receptor antagonist","level":4,"score":0.26420000195503235},{"id":"https://openalex.org/C2779922275","wikidata":"https://www.wikidata.org/wiki/Q1129105","display_name":"Diabetic nephropathy","level":3,"score":0.25769999623298645}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:CiteSeerX.psu:10.1.1.860.2203","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.860.2203","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://diabetes.diabetesjournals.org/content/early/2012/08/30/db12-0317.full.pdf","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2008125614","https://openalex.org/W3108481511","https://openalex.org/W4295872548","https://openalex.org/W2023623185","https://openalex.org/W4386407730","https://openalex.org/W4406404750","https://openalex.org/W2606777141","https://openalex.org/W4290963687","https://openalex.org/W4210723552","https://openalex.org/W2092777567"],"abstract_inverted_index":{"Humans":[0],"with":[1,16,47],"type":[2,56],"1":[3,57],"diabetes":[4],"mellitus":[5],"(DM)":[6],"are":[7],"subject":[8],"to":[9,115],"the":[10],"development":[11],"of":[12,34,55,68,118],"diabetic":[13],"leukoencephalopathy":[14],"(DLE)":[15],"cog-nitive":[17],"decline,":[18],"brain":[19,125],"atrophy,":[20],"and":[21,32,76,81,92,96,99],"white":[22],"matter":[23],"abnormalities.":[24],"We":[25],"examined":[26],"advanced":[27],"glycation":[28],"end":[29],"products":[30],"(AGE)":[31],"upregu-lation":[33],"their":[35],"receptor":[36],"(RAGE)":[37],"stimulated":[38],"by":[39],"persistent":[40],"hypergly-cemia":[41],"as":[42],"a":[43,51],"causative":[44],"pathway,":[45],"intervening":[46],"RAGE":[48,70],"blockade":[49],"in":[50],"murine":[52],"DLE":[53],"model":[54],"(streptozotocin)":[58],"DM.":[59],"Over":[60],"8":[61,114],"months,":[62,124,129],"DM":[63,108],"mice":[64,75,109],"received":[65],"intraperitoneal":[66],"injections":[67],"soluble":[69],"or":[71],"placebo":[72],"alongside":[73],"non-DM":[74],"RAGE2/2":[77],"mice.":[78],"Cognitive":[79],"testing":[80],"magnetic":[82],"resonance":[83],"imaging":[84],"(T2,":[85],"magnetiza-tion":[86],"transfer,":[87],"diffusion":[88],"tensor":[89],"imaging),":[90],"neuronal":[91],"oligodendrog-lial":[93],"counts,":[94],"synaptic":[95],"myelin":[97],"measures,":[98],"RAGE\u2013nuclear":[100],"factor":[101],"(NF)-kB":[102],"pathway":[103],"assessment":[104],"was":[105],"performed":[106],"serially.":[107],"developed":[110],"cognitive":[111],"deficits":[112],"after":[113,122,127],"20":[116],"weeks":[117],"DM,":[119],"oli-godendroglial":[120],"loss":[121],"3":[123],"atrophy":[126],"5":[128]},"counts_by_year":[],"updated_date":"2026-08-26T07:47:46.906454","created_date":"2025-10-27T00:00:00"}